Cell and Gene Therapy

Cell and Gene Therapy

With personalised cancer vaccines on the rise, is manufacturing scalable yet?

Life Science

How is cell and gene therapy innovation adapting to a changing investment landscape? Insights from TTP’s Cell & Gene panel event

Life Science

How can you prove 99.9% reliability? A challenge in automating and scaling cell therapies

Life Science

What failure rate are we willing to accept in cell therapy manufacture? Insights from medical device development

Life Science

Special Delivery: can advanced intracellular delivery enable superior cell therapies for solid tumour treatment – and beyond?

Life Science

Only a ‘click’ away: click chemistry transforms life science applications

Life Science

Driving Cell Therapy Innovation: Applying Key Lessons from the Evolution and Commercialization of Protein-Based Therapies

Life Science

Predicting failure rates in cell therapy manufacturing: is one in a million good enough?

Life Science

How many cells should a therapeutic cell sorter sort? (Part 3)

Life Science

Who should lead the charge in cell therapy manufacturing?

Life Science

How many cells should a therapeutic cell sorter sort? (Part 2)

Life Science

How many cells should a therapeutic cell sorter sort? (Part 1)